This is a translation of a pressrelease in Swedish from December 3rd 2018. Kancera AB announced today that the company has entered into an Research and Option agreement with Grünenthal, a leading pharmaceutical company in pain research and management. As part of...
Read MorePERIOD JAN – SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF • Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to SEK 0.1 million (SEK 0.0 million). • R&D...
Read MoreHere follows a translation of a Swedish press release from November 23th 2018. Kancera announces that terms have been prepared for a shareholders' decision on investment in the company by Global Corporate Finance (GCF), New York. The investment, which covers a maximum...
Read MoreKancera AB today announced that the article entitled "Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination" has been published by researchers from Karolinska Institutet and Kancera AB in the journal Nature Communications1. The article documents the molecular mechanisms that give the small...
Read MoreKancera AB (publ) hereby reports on project activities and status for the preparation and implementation of a clinical study in cardiovascular inflammation associated with myocardial infarction. In the cancer area, it is announced that the research project funded by SWElife has been...
Read MorePERIOD 1 JAN – 30 JUNE 2018 IN BRIEF • Net sales for the period amounted to MSEK 0.0 (0.1 million). Sales for the second quarter were 0.0 MEK (0.1 M) • R & D expenses for the period amounted to SEK 20.8...
Read MoreThis is a translation of the Swedish press release published 2018-07-06. Kancera AB (publ) hereby announces that unique blockers (antagonists) of the Fractalkine system have been patented. Kancera intends to further develop a new drug candidate from the patented antagonists, and this...
Read MorePERIOD 1 JAN – 31 MARCH 2018 IN BRIEF • Net sales amounted to SEK 0 million (0 million) • R & D expenses amounted to SEK 11.8 million (8.3 M) • Operating profit amounted to SEK -12.5 million (-9.7 million) •...
Read MoreToday, Friday, April 27, 2018 is the last day of trading in Kancera’s share, including the right to participate in the rights issue. Otherwise, the following time plan applies (dates refer to 2018): Friday April 27th: Last day for trading...
Read MoreKancera AB intends to provide new information about the company's pharmaceutical projects during April in a prospectus that forms part of a proposed new share issue. For this reason, Kancera now communicates the following information: Kanceras HDAC6 inhibitor KAN0440262...
Read More